MicroBiopharm Japan Co., Ltd.

This company has operated as a GMP-compliant CDMO and supplier of its own products to worldwide customers since 1941, based on combined technologies in microbial fermentation, enzymatic engineering and synthesis, and holding FDA, EMA and PMDA certification. Its key capabilities include production for clinical and commercial stages, including microbial fermentation of recombinant proteins and peptides (up to 2,000 liters) and microbial fermentation of chemicals (30 to 100,000 liters), along with process development covering fermentation (strain improvement, gene manipulation, purification, scale-up, analytical work) and bioconversion (including P450 hydroxylation).